1Miettinen M, Lasota J. Gastrointestinal stromal tumor-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis [J]. Virchows Arch ,2001,438 : 1-12.
2Emory TS ,Sobin LH ,Lukes L,et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors:dependence on anatomic site[ J]. Am J Surg Pathol, 1999,23:82-87.
3Mazur MT,Clark HB.Gastric stromal tumors.Reappraisal of histogenesis [J]. Am J Surg Pathol, 1983,7:507-519.
4Corless CL, McGreevey L, Haley A,et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size[J]. Am J Patho1,2002,160 : 1567-1572.
5Deininger MW,Goldman JM,Melo JV.The molecular biology of chronic myeloid leukemia[J].Blood,2000,96:3343-3356.
6Goldman JM.Tyrosine-kinase inhibition in treatment of chronic myeloid leukaemia[J].Lancet,2000,355:1031-1032.
7Goss GA,Merriam P,Manola J,et al.Clinical and pathologicalcharacteristics of gastrointestinal stromal tumors (GIST)[J].Proc Am Soc Clin Oncol,2000,19:599a.
8Druker BJ,Lydon NB.Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia[J].J Clin Invest,2000,105:3-7.
9Miettinen M,Monihan JM,Sarlomo-Rikala M,et al.Gastrointestinal stromal tumors/smooth muscle tumors (GISTs) primary in the omentum and mesentery:clinicopathologic and immunohistochemical study of 26 cases[J].Am J Surg Pathol,1999,23:1109-1118.
10Blanke CD,von Mehren M,Joensuu H,et al.Evaluation of the safety and efficacy of an oral molecularly-targeted therapy,STI571,in patients(Pts) with unresectable or metastatic gastrointestinal stromal tumors (GISTs) expressing c-kit (CD117)[J].Proc Am Soc Cl
